<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403893</url>
  </required_header>
  <id_info>
    <org_study_id>2753</org_study_id>
    <nct_id>NCT04403893</nct_id>
  </id_info>
  <brief_title>Feasibility and Safety of a Dedicated Biliary Stent for Transmural EUS-guided Hepatico-gastrostomy: the FIT Study</brief_title>
  <acronym>FIT</acronym>
  <official_title>Feasibility and Safety of a Dedicated Biliary Stent for Transmural EUS-guided Hepatico-gastrostomy: the FIT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the major roles of interventional EUS is biliary drainage (EUS-BD) as an alternative&#xD;
      to ERCP-based biliary decompression.&#xD;
&#xD;
      In fact, even when performed by expert endoscopists, ERCP-based stenting fails in 5% of&#xD;
      cases. In these cases, standard alternative approaches include surgical bypass and&#xD;
      percutaneous transhepatic cholangiography and biliary drainage (PTBD). However, these&#xD;
      procedures are associated with higher patient discomfort and prolonged hospital stay.&#xD;
&#xD;
      The most diffuse approach for EUS-BD are choledochoduodenostomy (CDS) or hepaticogastrostomy&#xD;
      (HGS). As a matter of fact, since dedicate devices as lumen apposing metal stents (LAMS),&#xD;
      have been adopted for CDS, we have been witnessing the escalation of such procedure.&#xD;
&#xD;
      On the other hand, the diffusion of EUS-HGS is still limited due to the complexity of the&#xD;
      procedure and the lack of dedicated devices. However, recently a dedicated stent was&#xD;
      conceived as asymmetrically covered and shaped in order to have its uncovered, tubular end&#xD;
      into the intrahepatic ducts and the covered, flanged end into the gastric cavity, to reduce&#xD;
      the risk of migration. The developement of such stent could further increase both the&#xD;
      technical feasibility and the clinical outcomes of HGS in order to explore the whole&#xD;
      potential of this procedure and to definitively find its role in biliary drainage algorithm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AE and SAE events</measure>
    <time_frame>12 Months</time_frame>
    <description>To assess the technical safety for EUS-guided hepaticogastrostomy.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Malignant Bilio-pancreatic Diseases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HANARO biliary stent placement</intervention_name>
    <description>HANARO biliary stent placement</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with malignant bilio-pancreatic diseases with an indication to undergo biliary&#xD;
        stent positioning for biliary drainage after ERCP failure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ subjects with malignant bilio-pancreatic diseases with an indication to undergo biliary&#xD;
        stent positioning for biliary drainage after ERCP failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 y&#xD;
&#xD;
          -  Contra-indication for endoscopy or interventional radiology&#xD;
&#xD;
          -  Unsigned informing consent form, ICF&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Anderloni, MD</last_name>
    <phone>0039-02-82247308</phone>
    <email>andrea.anderloni@umanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Endoscopy Unit, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Repici, MD</last_name>
      <phone>+39282247493</phone>
      <email>alessandro.repici@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Repici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Anderloni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta Maselli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Carrara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Fugazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessia Galtieri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaia Pellegatta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

